Den Europæiske Union - dansk - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - graft afvisning - immunosuppressiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

elanco gmbh - benazepril-hydrochlorid, pimobendan - ace-hæmmere, kombinationer - hunde - til behandling af kongestiv hjertesvigt på grund af atrioventrikulær ventilinsufficiens eller dilateret kardiomyopati hos hunde.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

olympus biotech international limited - eptotermin alfa - tibial frakturer - lægemidler til behandling af knoglesygdomme, bone morphogenetic protein - behandling af nonunion af tibia med en varighed på mindst 9 måneder, sekundært for traumer hos skeletmodne patienter, i tilfælde hvor tidligere behandling med autograft er mislykket eller brug af autograft er ufejlbarlig.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

laboratoires smb s.a. - fenofibrat, pravastatin - dyslipidæmi - lipid modificerende midler - pravafenix er indiceret til behandling af høj-koronar--hjertesygdom (chd)-risikerer voksne patienter med blandet dyslipidaemia kendetegnet ved høje triglycerider og lav hdl-cholesterol (c) niveauer hvis ldl-c niveauer er tilstrækkeligt kontrolleret under på en behandling med pravastatin-40-mg monoterapi.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

proveca pharma limited - enalapril (maleate) - hjertefejl - agenter, der virker på renin-angiotensinsystemet - treatment of heart failure.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - mavacamten - cardiomyopathy, hypertrophic - andre hjertepræparater - treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmacodane aps - simvastatin - filmovertrukne tabletter - 10 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmacodane aps - simvastatin - filmovertrukne tabletter - 20 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

pharmacodane aps - simvastatin - filmovertrukne tabletter - 40 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - simvastatin - filmovertrukne tabletter - 20 mg